Evidence-based Findings
Treatment Efficacy and Individualized Dosing
Growth hormone treatment in children shows significant variability in response when using standard weight-based dosing [5]. Research demonstrates that individualized GH doses based on individual responsiveness can reduce growth response variability by 32% compared to standard dosing [5]. In a 2-year multicenter study of 153 short prepubertal children with GH deficiency or idiopathic short stature, both individualized dosing (17-100 μg/kg/day) and standard dosing (43 μg/kg/day) achieved similar height gains of approximately 1.3 standard deviation scores [5].
Metabolic Effects During Treatment
GH treatment in prepubertal children significantly decreases serum adiponectin levels, with the decrease correlating to growth response [4]. In a study of 94 short prepubertal children, adiponectin levels dropped from 14.5 ± 5.71 to 12.5 ± 5.34 μg/ml after one year of treatment [4]. The magnitude of adiponectin decrease showed strong correlations with first-year growth response (r = -0.47, p < 0.0001) [4].
Healthcare Disparities
Significant disparities exist in pediatric growth evaluation and treatment, with overevaluation/treatment of White males and under-evaluation/treatment of females and children from minoritized groups [2]. These disparities require a comprehensive approach to improve healthcare access, increase provider education, and address structural biases [2].
Population-Specific Considerations
International growth standards like WHO charts may not fully capture growth patterns in diverse populations, potentially leading to misclassification and reduced effectiveness of GH therapy interventions [3]. Regional genetic variants, such as FBN1 (E1297G) in Peru, and modulators like GHR exon 3 deletion, ACAN, and NPR2, influence GH therapy response [3].
Established Clinical Knowledge
Based on standard clinical practice, growth hormone therapy is indicated for several pediatric conditions:
- Growth hormone deficiency (both isolated and multiple pituitary hormone deficiency)
- Idiopathic short stature in children significantly below normal height percentiles
- Turner syndrome
- Chronic kidney disease with growth failure
- Small for gestational age children who fail to demonstrate catch-up growth
Standard clinical practice indicates that treatment typically involves:
- Daily subcutaneous injections
- Regular monitoring of growth velocity and IGF-1 levels
- Assessment for potential side effects including glucose intolerance and increased intracranial pressure
- Consideration of pubertal timing and bone age advancement
Limitations
The available sources primarily focus on treatment response variability, metabolic effects, and healthcare disparities rather than comprehensive treatment protocols. Specific dosing guidelines, contraindications, and detailed safety profiles would require additional clinical references for complete coverage.